Hansa Raises More Cash For Pipeline With Genovis Stake Sale
The Swedish group has sold its stake in Genovis, raising about $9.6m that will help advance lead candidate imlifidase.
You may also be interested in...
Start-up Insitro will attempt to optimize up to five NASH targets for Gilead under three-year alliance. Catalent buys gene therapy CDMO Paragon for $1.2bn, Boehringer partners with PureTech in GI cancer, while Fibrocell inks gene therapy pact with Castle Creek.
The Swiss major, which is already signed up to help produce Pfizer and BioNTech's COVID-19 vaccine, is offering its services to CureVac to produce its mRNA vaccine.
Stefan Schulze, CEO of the Swiss iron deficiency and kidney disease specialist, tells Scrip that Vifor's reputation as a go-to industry partner should result in at least two more licensing deals or product acquisitions in 2021.